PACC1: A Promising Drug Target for Acid-Sensitive Outward-Rectifying Anion Channels

Target Name: PACC1

NCBI ID: G55248

PACC1

PACC1: A Promising Drug Target for Acid-Sensitive Outward-Rectifying Anion Channels

Abstract:

Acid-sensitive outward-rectifying anion channels (ASORs) play a crucial role in various physiological processes, including neurotransmission and hormone signaling. PACC1, a recently identified protein, has been shown to modulate ASOR function in various cell types. In this article, we review the current understanding of PACC1 function, its potential as a drug target, and its implications for future research.

Introduction:

Acid-sensitive outward-rectifying anion channels (ASORs) are a diverse family of transmembrane proteins that play a critical role in various physiological processes, including neurotransmission and hormone signaling. These channels are characterized by their ability to transmit anions through their channels in response to changes in pH, allowing them to regulate the concentration of positively charged ions in the cytosol. ASORs are highly conserved across various species, providing a valuable tool for understanding the fundamental mechanisms of ion transport and signaling.

PACC1: A Unique ASOR

PACC1, also known as TRPV4, is a recently identified ASOR that is expressed in various tissues and cell types. It is characterized by its unique structure, which consists of a periplasmic loop and a cytoplasmic tail. In addition to its unique structure, PACC1 is also unique in its ability to modulate ASOR function.

PACC1 function:

PACC1 is involved in the regulation of a wide range of cellular processes, including neurotransmission and hormone signaling. Its function is primarily determined by its ability to modulate the activity of other ASORs. PACC1 has been shown to modulate the activity of both positive and negative ASORs, allowing it to play a crucial role in the regulation of ion transport and signaling.

PACC1 as a drug target:

PACC1's unique function makes it an attractive drug target for a variety of therapeutic applications. Given its involvement in the regulation of ASOR function, PACC1 may be a potential target for the treatment of a variety of disorders related to ion transport and signaling.

One potential mechanism by which PACC1 may be targeted is its role in modulating the activity of ASORs. By modulating the activity of ASORs, PACC1 may be able to alter the sensitivity of these channels to various ions, leading to changes in cellular behavior. Additionally, PACC1 may also be involved in the regulation of ASORs' intracellular signaling pathways, providing a potential target for therapeutic intervention.

Conclusion:

In conclusion, PACC1 is a promising drug target for ASOR function. Its unique structure and function make it an attractive target for the development of new therapeutic strategies. Further research is needed to fully understand PACC1's role in ASOR function and its potential as a drug target.

Protein Name: Proton Activated Chloride Channel 1

Functions: Proton-activated chloride channel that mediates import of chloride ion in response to extracellular acidic pH (PubMed:31023925, PubMed:31318332). Involved in acidosis-induced cell death by mediating chloride influx and subsequent cell swelling (PubMed:31023925, PubMed:31318332)

The "PACC1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PACC1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets